
Loading, please wait...

Loading, please wait...

Idiopathic Granulomatous Mastitis (IGM) is a chronic inflammatory breast condition that frequently relapses. Clinicians often struggle to predict which patients will face a return of symptoms. However, recent findings suggest that the M-score IGM recurrence correlation offers a vital prognostic tool. By quantifying symptom severity at the initial diagnosis, medical professionals can better identify high-risk individuals.
Researchers analyzed 90 patients with histopathologically confirmed IGM. They utilized the M-score to provide objective data on clinical severity. The results showed a significant link between initial scores and future relapse. For instance, patients presenting with abscesses had a recurrence rate of 93.18%. In contrast, those without abscesses only saw a 60.87% recurrence rate. Furthermore, the data indicates that higher initial scores correlate strongly with a higher probability of relapse.
The study highlights that higher initial M-scores directly correspond to increased disease recurrence. Consequently, this scoring system helps surgeons and gynecologists tailor follow-up protocols. Physicians should implement aggressive monitoring for patients with elevated scores or abscess formation. Using these objective metrics improves patient counseling and long-term care strategies. Additionally, clinicians can better allocate resources to patients who require intensive therapy.
The M-score provides an objective measure of symptom severity in Idiopathic Granulomatous Mastitis. It helps clinicians predict the likelihood of disease recurrence and evaluate treatment responses more accurately.
Abscesses significantly increase the risk of disease relapse. According to recent research, patients with abscesses faced a recurrence rate of over 93%, compared to approximately 61% for those without.
IGM is a chronic, inflammatory condition prone to relapses. Predicting recurrence allows doctors to implement more intensive follow-up and adjust treatment plans early to manage high-risk cases effectively.
Disclaimer: This content is for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for professional clinical judgment. Refer to the latest local and national guidelines for clinical practice.
References
Ötegeçeli MA et al. Can M-score be used to predict recurrence in IGM patients? Eur J Med Res. 2026 Feb 14. doi: 10.1186/s40001-026-04053-0. PMID: 41691333.
Yilmaz T, Gurel B, et al. Scoring Idiopathic Granulomatous Mastitis: An Effective System for Predicting Recurrence? Eur J Breast Health. 2018; 14(2): 112–116.
Akcan A, et al. Factors Associated with Recurrence in Idiopathic Granulomatous Mastitis. J Invest Surg. 2019.
"
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.


New study finds initial M-scores and abscess presence significantly predict the risk of recurrence in Idiopathic Granulomatous Mastitis patients....
8 months ago

Following regulatory scrutiny from FSSAI regarding promotional representations and lean muscle preservation claims, Dr. Reddy's Laboratories and Nestlé Health Science are currently reviewing the branding and marketing strategy for their joint nutritional supplement Celevida GLP+.
Today

Demanding exhaustive hormonal profiling can inadvertently discourage clinical studies involving females. Methodological standards must align with the specific scientific question to expand, not restrict, equitable evidence for women.
Today

The Directorate General of Health Services directs Indian states to halt the hazardous reuse and reprocessing of single-use medical devices. Discover regulatory implications under the Drugs and Cosmetics Act, critical infection risks, legal liabilities, and operational changes required across clinical specialties.
Today

A novel calcium polyphosphate coacervate enables injectable bone implants with in situ hierarchical porosity via phase separation and gas foaming, significantly enhancing cell proliferation, energy metabolism, and osteogenic differentiation for minimally invasive bone defect repair.
Today

India is advancing preventive healthcare by integrating genomics, artificial intelligence, and quantum technologies. With the SANGAM programme sequencing one million Indian genomes, clinicians can unlock personalized therapies, detect cardiometabolic risks early, and curb the burden of diabetes and heart disease.
Today